Paloma Giangrande appointed for a second term as the editor-in-chief of Molecular Therapy Nucleic Acids

Dr. Giangrande, an internationally recognized RNA pioneer and executive with over 20 years of expertise across academia and industry, has been appointed for a second term as editor-in-chief of Molecular Therapy Nucleic Acids (MTNA). She has served as editor-in-chief since 2022, and her second five-year term will begin in January 2027. During her first term, she guided MTNA through an era of unprecedented growth in nucleic acid therapeutics. Under her leadership, the journal expanded its scope to include computational biology and AI/machine-learning applications.